BiPar Sciences' veteran team is composed of industry and clinical leaders working to transform cancer therapy. This team brings expertise in all of the aspects necessary to build a successful biopharmaceutical company. Management and advisors have played a central role in the successful development of several high-profile cancer therapies, such as Herceptin® (trastuzumab), Velcade® (bortezomib) and Doxil® (doxorubicin HCl liposome injection).
Hoyoung Huh, M.D., Ph.D.
President and Chief Executive Officer
Dr. Huh brings exceptional experience in product development and business development to BiPar Sciences. Prior to joining BiPar Sciences, Dr. Huh served as Chief Operating Officer and Head of the PEGylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases.
At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies, including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG, and Roche Holding Ltd. Prior to Nektar, Dr. Huh was a partner at McKinsey and Company, where he focused primarily in the biopharmaceutical sector in the U.S., Europe and Asia with areas of expertise in licensing, mergers and acquisitions, and innovative product launches.
As an industry thought leader, Dr. Huh speaks frequently about licensing, mergers and acquisitions, innovative product development and commercialization strategies. He currently serves on the Board of Directors at BayBio, a biotechnology industry association, and at Nektar Therapeutics (NASDAQ: NKTR). Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and an A.B. in Biochemistry from Dartmouth College.
Barry Sherman, M.D.
Executive Vice President, Development
Dr. Sherman has more than 30 years of experience in academic and pharmaceutical biomedical research. He served as President and CEO of Anergen Inc., a founder of Pain Therapeutics, Inc., and as Genentech's first Senior Vice President and Chief Medical Officer. He has also been a board member and consultant to several biotechnology and pharmaceutical companies.
Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and Endocrinology at the University of Iowa-College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the National Institutes of Health-sponsored Clinical Research Center.
Dr. Sherman is a graduate of the University of Michigan in Ann Arbor, where he received both his A.B. and M.D. degrees with honors. He completed his clinical and research training at the Albert Einstein College of Medicine in New York, the NIH in Bethesda, Maryland, and the University of Michigan. He has contributed more than 125 publications to the scientific literature, including articles, chapters and books resulting from his NIH-funded laboratory and human investigation and results from the study of new pharmaceuticals.
Eric D. Malek
Vice President, Corporate Development
Mr. Malek joined BiPar Sciences Inc. as Vice President, Corporate Development, in August 2007. Prior to that he was Vice President, Corporate Development, at Allos Therapeutics, where he was responsible for all in- and out-licensing, new product planning, and portfolio management. He led the effort to acquire Allos's lead product candidate Pralatrexate, currently in an SPA-approved registration trial for Peripheral T-Cell Lymphoma.
From 1994 to 2000, Mr. Malek held various positions in Corporate Development at NeXstar Pharmaceuticals, Gilead Sciences, Ilex Oncology, and Research Corporation Technologies. Prior to that he worked in sales at Bio-Rad Laboratories, and in research as an Associate with the Janssen Research Foundation, as well as a Research Assistant at both the University of Michigan's Protein Chemistry Facility and the University of Arizona Department of Pharmacology.
Mr. Malek received an M.B.A. in Finance and Marketing at the University of Michigan, and a B.A. in Biochemistry at the University of Arizona.
John Schembri
Chief Financial Officer
Mr. Schembri joined BiPar in 2007 after more than a decade of service to some of biotechnology's most successful and innovative companies. He was Vice President of Finance and Controller of Sirna Therapeutics Inc. until it was sold in December 2006 to Merck & Co. for $1.1 billion. At Sirna, he managed all financial activities involved in the sale of the company to Merck. Prior to joining Sirna, Mr. Schembri was Director of Finance and Controller at Cell Genesys Inc. He has also held similar positions at Cor Therapeutics Inc. and Telik Inc.
Deborah A. Thomas, Ph.D.
Vice President, Regulatory Affairs
Dr. Thomas joined BiPar in October 2007 as Vice President, Regulatory Affairs. Prior to joining BiPar, Dr. Thomas spent the previous 17 years at Genentech, where she held senior positions in Toxicology, Product Portfolio Management, and Regulatory Affairs. As a senior director in Regulatory Affairs, Dr. Thomas oversaw products moving from late-stage research and development into Phase I clinical testing. Prior to that, she served as Project Team Leader for Avastin, pertuzumab and Raptiva in the Product Portfolio Management Department.
Prior to joining Genentech, Dr. Thomas began her career in the pharmaceutical industry as a toxicologist at Syntex Research.
Dr. Thomas received her Ph.D. in Toxicology and her B.S. in Microbiology from the University of Kentucky. She completed her postdoctoral training at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, North Carolina. She is also a board-certified diplomate of the American Board of Toxicology.
Charles Bradley, Ph.D.
Vice President, Clinical Development
Dr. Bradley joined BiPar in April 2005 as Vice President, Clinical Development. From 2000 to 2005, Dr. Bradley held a variety of positions with Amgen, both in the Medical Affairs and Clinical Development organizations. He had overall clinical operational responsibilities for programs across the oncology and nephrology therapeutic areas.
Prior to joining Amgen, Dr. Bradley held senior positions in the clinical development group at Guilford Pharmaceuticals and in the Clinical Pharmacology department at Hoechst-Roussel Pharmaceuticals. Dr. Bradley also served as a pharmacokinetic reviewer for more than three years with the U.S. Food and Drug Administration.
Dr. Bradley received his Ph.D. in Bioanalytical Chemistry from the University of Delaware, and obtained post-doctoral training in clinical pharmacology from the Uniformed Services University in Bethesda, Maryland. He also is a board-certified diplomate in Applied Pharmacology of the American Board of Clinical Pharmacology.
Valeria Ossovskaya, Ph.D.
Director, Preclinical Development
Dr. Ossovskaya joined BiPar Sciences as a member of our preclinical and drug discovery team. She brings over 15 years of broad experience in oncology, virology, molecular genetics and proteomics.
Prior to BiPar, Dr. Ossovskaya worked as an Assistant Research Professor at the University of California, San Francisco (UCSF), where she investigated molecular mechanisms of neuronal functional plasticity and differentiation. Prior to UCSF, she served as a Scientist in Oncology and Technical Development Programs at Rigel Pharmaceuticals for several years. Valeria's experience includes several research collaborations with a number of biotech and pharmaceutical companies, including Johnson & Johnson, Janssen Pharmaceutica, Novartis and Oxford Gene Technologies.
Dr. Ossovskaya holds an M.S. in Biochemistry from Moscow State University and a Ph.D. in Molecular Biology from the Russian Academy of Science. Her graduate and post-doctoral training was completed at the University of Illinois at Chicago and at the University of California, San Francisco. Her awards and honors include the International Union Against Cancer Award (Switzerland), the Humboldt University of Berlin Award (Germany) and the National Cancer Institute Award (NIH, USA). Dr. Ossovskaya has published a number of scientific papers in peer-review journals and holds several U.S. and international patents.
Read about our Board of Directors
Read about our Scientific/Clinical Advisory Board
Read about our current investors
